Digital health guidances clarify which techs FDA will review

A pair of guidances released by FDA on Thursday clarifies what digital health technologies do and do not fall under the agency’s review process.

FDA revised draft guidance on clinical decision support software after stakeholders asked that the agency consider a risk-based categorization of software products based on the risk to

Read the full 512 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE